-
1
-
-
0036237822
-
Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma
-
DOI 10.1053/jhep.2002.33156
-
Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002. (Pubitemid 34454013)
-
(2002)
Hepatology
, vol.35
, Issue.5
, pp. 1164-1171
-
-
Lo, C.-M.1
Ngan, H.2
Tso, W.-K.3
Liu, C.-L.4
Lam, C.-M.5
Poon, R.T.-P.6
Fan, S.-T.7
Wong, J.8
-
2
-
-
0037308133
-
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
-
DOI 10.1053/jhep.2003.50047
-
Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
-
(2003)
Hepatology
, vol.37
, Issue.2
, pp. 429-442
-
-
Llovet, J.M.1
Bruix, J.2
-
3
-
-
0033503797
-
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: Long-term results of treatment and prognostic factors
-
DOI 10.1097/00000658-199902000-00009
-
Poon RT, Fan ST, Lo CM, Liu CL and Wong J: Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229: 216-222, 1999. (Pubitemid 30191795)
-
(1999)
Annals of Surgery
, vol.229
, Issue.2
, pp. 216-222
-
-
Poon, R.T.-P.1
Fan, S.-T.2
Lo, C.-M.3
Liu, C.-L.4
Wong, J.5
-
4
-
-
0642338431
-
Selection Criteria for Repeat Hepatectomy in Patients with Recurrent Hepatocellular Carcinoma
-
DOI 10.1097/01.sla.0000094549.11754.e6
-
Minagawa M, Makuuchi M, Takayama T and Kokudo N: Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238: 703-710, 2003. (Pubitemid 38182262)
-
(2003)
Annals of Surgery
, vol.238
, Issue.5
, pp. 703-710
-
-
Minagawa, M.1
Makuuchi, M.2
Takayama, T.3
Kokudo, N.4
-
5
-
-
78649709091
-
Liver transplantation for hepatocellular carcinoma: The Kyoto experience
-
Takada Y and Uemoto S: Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci 17: 527-532, 2010.
-
(2010)
J Hepatobiliary Pancreat Sci
, vol.17
, pp. 527-532
-
-
Takada, Y.1
Uemoto, S.2
-
6
-
-
77957603190
-
Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting
-
Thomas MB, Jaffe D, Choti MM, et al: Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28: 3994-4005, 2010.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3994-4005
-
-
Thomas, M.B.1
Jaffe, D.2
Choti, M.M.3
-
7
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
8
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
-
9
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
DOI 10.1158/0008-5472.CAN-04-1443
-
Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004. (Pubitemid 39331023)
-
(2004)
Cancer Research
, vol.64
, Issue.19
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
Chen, C.7
Zhang, X.8
Vincent, P.9
McHugh, M.10
Cao, Y.11
Shujath, J.12
Gawlak, S.13
Eveleigh, D.14
Rowley, B.15
Liu, L.16
Adnane, L.17
Lynch, M.18
Auclair, D.19
Taylor, I.20
Gedrich, R.21
Voznesensky, A.22
Riedl, B.23
Post, L.E.24
Bollag, G.25
Trail, P.A.26
more..
-
10
-
-
33847118123
-
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
-
DOI 10.1007/s00280-006-0393-4
-
Chang YS, Adnane J, Trail PA, et al: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574, 2007. (Pubitemid 46295136)
-
(2007)
Cancer Chemotherapy and Pharmacology
, vol.59
, Issue.5
, pp. 561-574
-
-
Chang, Y.S.1
Adnane, J.2
Trail, P.A.3
Levy, J.4
Henderson, A.5
Xue, D.6
Bortolon, E.7
Ichetovkin, M.8
Chen, C.9
McNabola, A.10
Wilkie, D.11
Carter, C.A.12
Taylor, I.C.A.13
Lynch, M.14
Wilhelm, S.15
-
11
-
-
59849120213
-
Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]
-
Hoffmann K, Glimm H, Radeleff B, et al: Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer 8: 349, 2008.
-
(2008)
BMC Cancer
, vol.8
, pp. 349
-
-
Hoffmann, K.1
Glimm, H.2
Radeleff, B.3
-
12
-
-
78349298645
-
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial
-
Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304: 2154-2160, 2010.
-
(2010)
JAMA
, vol.304
, pp. 2154-2160
-
-
Abou-Alfa, G.K.1
Johnson, P.2
Knox, J.J.3
-
13
-
-
77953124105
-
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
-
Hsu CH, Shen YC, Lin ZZ, et al: Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53: 126-131, 2010.
-
(2010)
J Hepatol
, vol.53
, pp. 126-131
-
-
Hsu, C.H.1
Shen, Y.C.2
Lin, Z.Z.3
-
14
-
-
80054722090
-
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma
-
Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N and Geschwind JF: Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29: 3960-3967, 2011.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3960-3967
-
-
Pawlik, T.M.1
Reyes, D.K.2
Cosgrove, D.3
Kamel, I.R.4
Bhagat, N.5
Geschwind, J.F.6
-
15
-
-
79959373568
-
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma
-
Cabrera R, Pannu DS, Caridi J, et al: The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 34: 205-213, 2011.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 205-213
-
-
Cabrera, R.1
Pannu, D.S.2
Caridi, J.3
-
16
-
-
84859750869
-
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
-
Petrini I, Lencioni M, Ricasoli M, et al: Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 69: 773-780, 2012.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 773-780
-
-
Petrini, I.1
Lencioni, M.2
Ricasoli, M.3
-
17
-
-
0033839749
-
Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines
-
Yamanaka T, Shiraki K, Sugimoto K, et al: Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32: 482-490, 2000.
-
(2000)
Hepatology
, vol.32
, pp. 482-490
-
-
Yamanaka, T.1
Shiraki, K.2
Sugimoto, K.3
-
18
-
-
0037204818
-
Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin
-
Shin EC, Seong YR, Kim CH, et al: Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 34: 114-122, 2002. (Pubitemid 34664327)
-
(2002)
Experimental and Molecular Medicine
, vol.34
, Issue.2
, pp. 114-122
-
-
Shin, E.-C.1
Seong, Y.R.2
Kim, C.H.3
Kim, H.4
Ahn, Y.S.5
Kim, K.6
Kim, S.J.7
Hong, S.-S.8
Park, J.H.9
-
19
-
-
34347246278
-
Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death
-
DOI 10.1016/j.ccr.2007.05.006, PII S153561080700150X
-
Ricci MS, Kim SH, Ogi K, et al: Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12: 66-80, 2007. (Pubitemid 47001783)
-
(2007)
Cancer Cell
, vol.12
, Issue.1
, pp. 66-80
-
-
Ricci, M.S.1
Kim, S.-H.2
Ogi, K.3
Plastaras, J.P.4
Ling, J.5
Wang, W.6
Jin, Z.7
Liu, Y.Y.8
Dicker, D.T.9
Chiao, P.J.10
Flaherty, K.T.11
Smith, C.D.12
El-Deiry, W.S.13
-
20
-
-
75449102003
-
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies
-
Koehler BC, Urbanik T, Vick B, et al: TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol 15: 5924-5935, 2009.
-
(2009)
World J Gastroenterol
, vol.15
, pp. 5924-5935
-
-
Koehler, B.C.1
Urbanik, T.2
Vick, B.3
-
21
-
-
84984559474
-
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3
-
Chen KF, Tai WT, Liu TH, et al: Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res 16: 5189-5199, 2010.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5189-5199
-
-
Chen, K.F.1
Tai, W.T.2
Liu, T.H.3
-
22
-
-
17544373837
-
Survivin promotes cell proliferation in human hepatocellular carcinoma
-
Ito T, Shiraki K, Sugimoto K, et al: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31: 1080-1085, 2000. (Pubitemid 30233232)
-
(2000)
Hepatology
, vol.31
, Issue.5
, pp. 1080-1085
-
-
Ito, T.1
Shiraki, K.2
Sugimoto, K.3
Yamanaka, T.4
Fujikawa, K.5
Ito, M.6
Takase, K.7
Moriyama, M.8
Kawano, H.9
Hayashida, M.10
Nakano, T.11
Suzuki, A.12
-
23
-
-
0042809497
-
Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma
-
DOI 10.1097/01.LAB.0000079328.76631.28
-
Okano H, Shiraki K, Inoue H, et al: Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83: 1033-1043, 2003. (Pubitemid 36899070)
-
(2003)
Laboratory Investigation
, vol.83
, Issue.7
, pp. 1033-1043
-
-
Okano, H.1
Shiraki, K.2
Inoue, H.3
Kawakita, T.4
Yamanaka, T.5
Deguchi, M.6
Sugimoto, K.7
Sakai, T.8
Ohmori, S.9
Fujikawa, K.10
Murata, K.11
Nakano, T.12
-
24
-
-
3042674026
-
Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma
-
Shiraki K, Sugimoto K, Yamanaka Y, et al: Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med 12: 705-708, 2003.
-
(2003)
Int J Mol Med
, vol.12
, pp. 705-708
-
-
Shiraki, K.1
Sugimoto, K.2
Yamanaka, Y.3
-
25
-
-
27744497446
-
Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death
-
Yamaguchi Y, Shiraki K, Fuke H, et al: Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep 14: 1311-1316, 2005.
-
(2005)
Oncol Rep
, vol.14
, pp. 1311-1316
-
-
Yamaguchi, Y.1
Shiraki, K.2
Fuke, H.3
-
26
-
-
79955979815
-
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy
-
Kim JW, Lee JO, Han SW, et al: Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. Am J Clin Oncol 34: 125-129, 2010.
-
(2010)
Am J Clin Oncol
, vol.34
, pp. 125-129
-
-
Kim, J.W.1
Lee, J.O.2
Han, S.W.3
-
27
-
-
33747830764
-
Hepatocellular carcinoma pathogenesis: From genes to environment
-
DOI 10.1038/nrc1934, PII NRC1934
-
Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687, 2006. (Pubitemid 44286000)
-
(2006)
Nature Reviews Cancer
, vol.6
, Issue.9
, pp. 674-687
-
-
Farazi, P.A.1
DePinho, R.A.2
-
28
-
-
54449083925
-
Molecular targeted therapies in hepatocellular carcinoma
-
Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
-
(2008)
Hepatology
, vol.48
, pp. 1312-1327
-
-
Llovet, J.M.1
Bruix, J.2
-
29
-
-
34547819299
-
The promise of TRAIL - Potential and risks of a novel anticancer therapy
-
DOI 10.1007/s00109-007-0194-1
-
Koschny R, Walczak H and Ganten TM: The promise of TRAIL potential and risks of a novel anticancer therapy. J Mol Med (Berl) 85: 923-935, 2007. (Pubitemid 47282789)
-
(2007)
Journal of Molecular Medicine
, vol.85
, Issue.9
, pp. 923-935
-
-
Koschny, R.1
Walczak, H.2
Ganten, T.M.3
-
30
-
-
52649109068
-
The TRAIL apoptotic pathway in cancer onset, progression and therapy
-
Johnstone RW, Frew AJ and Smyth MJ: The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8: 782-798, 2008.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 782-798
-
-
Johnstone, R.W.1
Frew, A.J.2
Smyth, M.J.3
-
31
-
-
77949686312
-
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells
-
Huang S and Sinicrope FA: Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 9: 742-750, 2010.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 742-750
-
-
Huang, S.1
Sinicrope, F.A.2
-
32
-
-
76249092117
-
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
-
Llobet D, Eritja N, Yeramian A, et al: The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 46: 836-850, 2010.
-
(2010)
Eur J Cancer
, vol.46
, pp. 836-850
-
-
Llobet, D.1
Eritja, N.2
Yeramian, A.3
-
33
-
-
13844267552
-
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines
-
DOI 10.1097/00001813-200502000-00003
-
Heim M, Scharifi M, Zisowsky J, et al: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16: 129-136, 2005. (Pubitemid 40250607)
-
(2005)
Anti-Cancer Drugs
, vol.16
, Issue.2
, pp. 129-136
-
-
Heim, M.1
Scharifi, M.2
Zisowsky, J.3
Jaehde, U.4
Voliotis, D.5
Seeber, S.6
Strumberg, D.7
-
34
-
-
33744791463
-
Wnt signaling: Is the party in the nucleus?
-
DOI 10.1101/gad.1424006
-
Willert K and Jones KA: Wnt signaling: is the party in the nucleus? Genes Dev 20: 1394-1404, 2006. (Pubitemid 43830647)
-
(2006)
Genes and Development
, vol.20
, Issue.11
, pp. 1394-1404
-
-
Willert, K.1
Jones, K.A.2
-
35
-
-
33947217823
-
Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia
-
DOI 10.1038/ncb1534, PII NCB1534
-
Kaidi A, Williams AC and Paraskeva C: Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210-217, 2007. (Pubitemid 46420864)
-
(2007)
Nature Cell Biology
, vol.9
, Issue.2
, pp. 210-217
-
-
Kaidi, A.1
Williams, A.C.2
Paraskeva, C.3
-
36
-
-
48549098557
-
Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin
-
Lim JH, Chun YS and Park JW: Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin. Cancer Res 68: 5177-5184, 2008.
-
(2008)
Cancer Res
, vol.68
, pp. 5177-5184
-
-
Lim, J.H.1
Chun, Y.S.2
Park, J.W.3
-
37
-
-
77957584397
-
O2 regulates stem cells through Wnt/beta-catenin signalling
-
Mazumdar J, O'Brien WT, Johnson RS, et al: O2 regulates stem cells through Wnt/beta-catenin signalling. Nat Cell Biol 12: 1007-1013, 2010.
-
(2010)
Nat Cell Biol
, vol.12
, pp. 1007-1013
-
-
Mazumdar, J.1
O'Brien, W.T.2
Johnson, R.S.3
-
38
-
-
80051481674
-
Wnt-beta-catenin signaling protects against hepatic ischemia and reperfusion injury in mice
-
Lehwald N, Tao GZ, Jang KY, Sorkin M, Knoefel WT and Sylvester KG: Wnt-beta-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology 141: 707-718, 2011.
-
(2011)
Gastroenterology
, vol.141
, pp. 707-718
-
-
Lehwald, N.1
Tao, G.Z.2
Jang, K.Y.3
Sorkin, M.4
Knoefel, W.T.5
Sylvester, K.G.6
|